Personal information

United States

Activities

Education and qualifications (4)

University of Toronto: Toronto, ON, CA

Masters of Science (Pharmacology)
Education
Source: Self-asserted source
Sherwin K. B. Sy

University of Toronto: Toronto, ON, CA

Honours Bachelors of Science (Pharmacology)
Education
Source: Self-asserted source
Sherwin K. B. Sy

University of Florida: Gainesville, Florida, US

Doctor of Philosophy (Pharmaceutical Sciences)
Education
Source: Self-asserted source
Sherwin K. B. Sy

Temple University: Philadelphia, PA, US

Masters of Science (Statistics)
Education
Source: Self-asserted source
Sherwin K. B. Sy

Professional activities (1)

Universidade Estadual de Maringá: Maringa, PR, BR

2015-06-01 to present | Adjunct Professor (Statistics)
Invited position
Source: Self-asserted source
Sherwin K. B. Sy

Works (50 of 84)

Items per page:
Page 1 of 2

The impact of aztreonam-clavulanic acid exposure on gene expression and mutant selection using a multidrug-resistant <i>E. coli</i>.

Microbiology spectrum
2025-02-11 | Journal article | Author
Contributors: Tongtong Lin; Zhang J; Diao S; Yan J; Zhang K; Cao J; Huang J; Wang Y; Lv Z; Shen X et al.
Source: Self-asserted source
Sherwin K. B. Sy

Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model

British Journal of Clinical Pharmacology
2024-12-30 | Journal article
Contributors: Sherwin K. B. Sy; Deok Yong Yoon; Christelle Darstein; Yiqun Yang; Kohinoor Dasgupta; Shruti Kapoor; Matthias Hoch; Kai Grosch
Source: check_circle
Crossref

Clinical Pharmacology of Asciminib: A Review

Clinical Pharmacokinetics
2024-11 | Journal article
Contributors: Matthias Hoch; Felix Huth; Paul William Manley; Ioannis Loisios-Konstantinidis; Francois Pierre Combes; Ying Fei Li; Yunlin Fu; Sherwin K. B. Sy; Vanessa Obourn; Abhijit Chakraborty et al.
Source: check_circle
Crossref

Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling.

Frontiers in microbiology
2024-10-07 | Journal article
Contributors: Wu M; Feng K; Wu X; Liu C; Zhu S; Martins FS; Yu M; Lv Z; Yan M; Sy SKB
Source: Self-asserted source
Sherwin K. B. Sy

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.

Clinical pharmacokinetics
2024-09-07 | Journal article
Contributors: Francois Pierre Combes; Sy SKB; Li YF; Lorenzo S; Dasgupta K; Kapoor S; Hoch M; Ho YY
Source: Self-asserted source
Sherwin K. B. Sy

Metabolomics unveil key pathways underlying the synergistic activities of aztreonam and avibactam against multidrug-resistant Escherichia coli.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
2024-05-09 | Journal article
Contributors: Zhou X; Zhang J; Chen J; Wang L; Yu M; Sy SKB; Yang H
Source: Self-asserted source
Sherwin K. B. Sy

Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy

Cancer Chemotherapy and Pharmacology
2024-04 | Journal article
Contributors: Yan Ji; Sherwin K. B. Sy
Source: check_circle
Crossref

Simultaneous Determination of Levo-tetrahydropalmatine and Naltrexone in Rat Plasma by LC-MS/MS and its Application in a Pharmacokinetic Study.

Current pharmaceutical biotechnology
2024-01 | Journal article
Contributors: Feng K; Sy SKB; Yu M; Lv Z; Yan M
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Comparative metabolomics reveal key pathways associated with the synergistic activities of aztreonam and clavulanate combination against multidrug-resistant Escherichia coli

mSystems
2023-12-21 | Journal article
Contributors: Jiayuan Zhang; Hai Yang; Lei Zhang; Zhihua Lv; Mingming Yu; Sherwin K. B. Sy; Yuanchao Zhan; Robert G. Beiko
Source: check_circle
Crossref

Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations

British Journal of Clinical Pharmacology
2023-09 | Journal article
Contributors: Frederico Severino Martins; José Eduardo Severino Martins; Patricia Severino; Pieter Annaert; Sherwin K. B. Sy
Source: check_circle
Crossref

Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?

Drug discovery today
2023-06 | Journal article
Contributors: Oo C; Zhang X; Sy SKB
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against <i>Acinetobacter baumannii</i>.

Frontiers in microbiology
2023-06 | Journal article
Contributors: Zhu S; Yue J; Wang X; Zhang J; Yu M; Zhan Y; Zhu Y; Sy SKB; Lv Z
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2023-04 | Journal article
Contributors: Zhang J; Song C; Wu M; Yue J; Zhu S; Zhu P; Oo C; Schlender JF; Lv Z; Zhu Y et al.
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease

Clinical Pharmacokinetics
2023-02 | Journal article
Contributors: Sherwin K. B. Sy; Chiaki Tanaka; Kai Grosch
Source: check_circle
Crossref

Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>

Pharmaceutics
2023-01 | Journal article | Author
Contributors: Jiayuan Zhang; Mengyuan Wu; Shuo Diao; Shixing Zhu; Chu Song; Jiali Yue; Frederico S. Martins; Peijuan Zhu; Zhihua Lv; Yuanqi Zhu et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase

Clinical Pharmacology & Therapeutics
2022-11 | Journal article
Contributors: François Pierre Combes; Ying Fei Li; Matthias Hoch; Sebastien Lorenzo; Yu‐Yun Ho; Sherwin K. B. Sy
Source: check_circle
Crossref

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant <i>Acinetobacter baumannii</i>.

Frontiers in microbiology
2022-11 | Journal article
Contributors: Zhang J; Diao S; Liu Y; Wang H; Liu Y; Zhu S; Feng K; Tang X; Oo C; Zhu P et al.
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases

Clinical Pharmacokinetics
2022-10 | Journal article
Contributors: Ying Fei Li; Francois Pierre Combes; Matthias Hoch; Sebastien Lorenzo; Sherwin K. B. Sy; Yu-Yun Ho
Source: check_circle
Crossref

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant <i>Acinetobacter baumannii</i>.

Frontiers in microbiology
2022-10 | Journal article
Contributors: Zhu S; Song C; Zhang J; Diao S; Heinrichs TM; Martins FS; Lv Z; Zhu Y; Yu M; Sy SKB
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases

Clinical Pharmacokinetics
2022-10 | Journal article
Contributors: Ying Fei Li; Francois Pierre Combes; Matthias Hoch; Sebastien Lorenzo; Sherwin K. B. Sy; Yu-Yun Ho
Source: check_circle
Crossref

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Clinical Pharmacokinetics
2022-10 | Journal article
Contributors: Shixing Zhu; Jiayuan Zhang; Zhihua Lv; Peijuan Zhu; Charles Oo; Mingming Yu; Sherwin K. B. Sy
Source: check_circle
Crossref

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant <i>Acinetobacter baumannii</i>.

Frontiers in microbiology
2022-09 | Journal article
Contributors: Zhu S; Zhang J; Song C; Liu Y; Oo C; Heinrichs MT; Lv Z; Zhu Y; Sy SKB; Deng P et al.
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose

Clinical and Translational Science
2022-09 | Journal article
Contributors: Yan Ji; Deborah Knee; Xinhui Chen; Anhthu Dang; Jennifer Mataraza; Babette Wolf; Sherwin K. B. Sy
Source: check_circle
Crossref

Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of <i>Riemerella anatipestifer</i> in Ducks.

Microbial drug resistance (Larchmont, N.Y.)
2022-06 | Journal article
Contributors: Zhang Y; Zhang R; Sy SKB; Li Z; Zhu S; Zhou M; Song C; Zhang J; Lv Z; Liu J et al.
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.

The Journal of antimicrobial chemotherapy
2021-08 | Journal article
Contributors: Feng K; Jia N; Zhu P; Sy S; Liu Y; Dong D; Zhu S; Zhang J; Liu Y; Martins FS et al.
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy.

Scientific reports
2021-05 | Journal article
Contributors: Fedrigo NH; Shinohara DR; Mazucheli J; Nishiyama SAB; Carrara-Marroni FE; Martins FS; Zhu P; Yu M; Sy SKB; Tognim MCB
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics

British Journal of Clinical Pharmacology
2021-03 | Journal article
Contributors: Frederico S. Martins; Peijuan Zhu; M. Tobias Heinrichs; Sherwin K. B. Sy
Source: check_circle
Crossref

Pharmacokinetic-Pharmacodynamic Characterization of a Topical Photochemotherapy Using Brosimum gaudichaudii in C56BL/6 Mice

Revista Brasileira de Farmacognosia
2021-03-15 | Journal article
Contributors: Frederico Severino Martins; Sherwin K. B. Sy; Edemilson Cardoso da Conceição; Maria José Vieira Fonseca; Osvaldo de Freitas
Source: check_circle
Crossref

Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver

The AAPS Journal
2020-09 | Journal article
Part of ISSN: 1550-7416
Source: Self-asserted source
Sherwin K. B. Sy

Melanogenic Effect and Toxicity Assessments of Standardized Extract of Brosimum gaudichaudii

Revista Brasileira de Farmacognosia
2020-08-21 | Journal article
Contributors: Frederico Severino Martins; Sherwin K. B. Sy; Edemilson Cardoso da Conceição; Maria José Vieira Fonseca; Osvaldo de Freitas
Source: check_circle
Crossref

Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii

Planta Medica
2020-01-22 | Journal article
Part of ISSN: 0032-0943
Part of ISSN: 1439-0221
Source: Self-asserted source
Sherwin K. B. Sy

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective.

Drug discovery today
2019-09 | Journal article
Contributors: Oo C; Sy SKB
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase

Antimicrobial Agents and Chemotherapy
2019-06 | Journal article
Contributors: James Albiero; Josmar Mazucheli; Juliana Pimenta dos Reis Barros; Marcia Maria dos Anjos Szczerepa; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Serubbabel Sy; Matthew Fidler; Sherwin K. B. Sy; Maria Cristina Bronharo Tognim
Source: check_circle
Crossref

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information

Microbial Drug Resistance
2019-06-19 | Journal article
Part of ISSN: 1076-6294
Part of ISSN: 1931-8448
Source: Self-asserted source
Sherwin K. B. Sy

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development

Clinical Pharmacokinetics
2019-05-11 | Journal article
Contributors: Sherwin K. B. Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Source: check_circle
Crossref

Physiologically-based pharmacokinetics of ziprasidone in pregnant women.

British journal of clinical pharmacology
2019-01 | Journal article
Contributors: Biesdorf C; Martins FS; Sy SKB; Diniz A
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central
grade
Preferred source (of 2)‎

Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs.

International journal of mycobacteriology
2018 | Journal article
Contributors: Heinrichs MT; May RJ; Heider F; Reimers T; B Sy SK; Peloquin CA; Derendorf H
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
2018-10 | Journal article
Contributors: Sy SKB; Zhuang L; Xia H; Schuck VJ; Nichols WW; Derendorf H
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation.

International journal of antimicrobial agents
2018-10 | Journal article
Contributors: Heinrichs MT; Drusano GL; Brown DL; Maynard MS; Sy SKB; Rand KH; Peloquin CA; Louie A; Derendorf H
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central
grade
Preferred source (of 2)‎

A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy
2018-05-01 | Journal article
Contributors: Sherwin K B Sy; Luning Zhuang; Huiming Xia; Marie-Eve Beaudoin; Virna J Schuck; Wright W Nichols; Hartmut Derendorf
Source: check_circle
Crossref

Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-04 | Journal article
Contributors: Rugo HS; Cortes J; Awada A; O'Shaughnessey J; Twelves CJ; Im SA; Hannah A; Lu L; Sy S; Caygill K et al.
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.

The AAPS journal
2018-03 | Journal article
Contributors: Zhu P; Sy SKB; Skerjanec A
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Cancer chemotherapy and pharmacology
2018-03 | Journal article
Contributors: Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Fixed-dose combinations: a potential means to boost drug development for selected drugs.

Drug discovery today
2017-11 | Journal article
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats.

International journal of antimicrobial agents
2017-10 | Journal article
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Experimental design and modeling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
2017-07 | Journal article
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central

Pharmacodynamic evaluation of fosfomycin against E. coli and Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin activities.

2017-06 | Journal article
Contributors: Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
Source: Self-asserted source
Sherwin K. B. Sy via Europe PubMed Central
grade
Preferred source (of 2)‎

Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms

CPT: Pharmacometrics & Systems Pharmacology
2017-02 | Journal article
Contributors: SKB Sy; L Zhuang; H Xia; M-E Beaudoin; VJ Schuck; H Derendorf
Source: Self-asserted source
Sherwin K. B. Sy via Crossref Metadata Search

Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model

Journal of Antimicrobial Chemotherapy
2017-01-10 | Journal article
Contributors: Sherwin K. B. Sy; Luning Zhuang; Marie-Eve Beaudoin; Philipp Kircher; Maria A. M. Tabosa; Noely C. T. Cavalcanti; Christian Grunwitz; Sebastian Pieper; Virna J. Schuck; Wright W. Nichols et al.
Source: Self-asserted source
Sherwin K. B. Sy via Crossref Metadata Search

Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development

Clinical Pharmacology: Current Topics and Case Studies
2016 | Other
Contributors: Sherwin K. B. Sy; Hartmut Derendorf
Source: Self-asserted source
Sherwin K. B. Sy via Crossref Metadata Search
Items per page:
Page 1 of 2

Peer review (2 reviews for 2 publications/grants)

Review activity for Cancer chemotherapy and pharmacology. (1)
Review activity for International journal of antimicrobial agents. (1)